Evidence map›Paper›PMID 35442945›Full record

ArticlePLoS computational biology2022

All2: A tool for selecting mosaic mutations from comprehensive multi-cell comparisons.

Vivekananda Sarangi, Yeongjun Jang, Milovan Suvakov, Taejeong Bae, Liana Fasching, Shobana Sekar, Livia Tomasini, Jessica Mariani, Flora M Vaccarino, Alexej Abyzov

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Vivekananda SarangiDepartment of Quantitative Health Sciences, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID 0000-0002-3070-8582
Yeongjun JangDepartment of Quantitative Health Sciences, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID 0000-0002-7816-3278
Milovan SuvakovDepartment of Quantitative Health Sciences, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID 0000-0002-5839-9611
Taejeong BaeDepartment of Quantitative Health Sciences, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID 0000-0002-4626-3725
Liana FaschingChild Study Center, Yale University, New Haven, Connecticut, United States of America.ORCID 0000-0002-6840-658X
Shobana SekarDepartment of Quantitative Health Sciences, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.ORCID 0000-0002-8273-9022
Livia TomasiniChild Study Center, Yale University, New Haven, Connecticut, United States of America.ORCID 0000-0001-7144-6964
Jessica MarianiChild Study Center, Yale University, New Haven, Connecticut, United States of America.
Flora M VaccarinoChild Study Center, Yale University, New Haven, Connecticut, United States of America.ORCID 0000-0003-2167-981X
Alexej AbyzovDepartment of Quantitative Health Sciences, Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Mayo Clinic · USYale University · US

Funding

Somatic Mosaicism in the Brain of Tourette SyndromeU01MH106876 · NIMH · YALE UNIVERSITY · PI VACCARINO, FLORA M · 2015 to 2019
$6.1M
Genomic mosaicism in developing human brainR01MH100914 · NIMH · YALE UNIVERSITY · PI GERSTEIN, MARK BENDER, VACCARINO, FLORA M · 2014 to 2018
$3.5M
Detection of somatic, subclonal and mosaic CNVs from sequencingU24CA220242 · NCI · MAYO CLINIC ROCHESTER · PI ABYZOV, ALEXEJ · 2018 to 2022
$2.6M
NCI NIH HHS U24 CA220242NIMH NIH HHS R01 MH100914NIMH NIH HHS U01 MH106876
6 · The paper itself

Abstract

Accurate discovery of somatic mutations in a cell is a challenge that partially lays in immaturity of dedicated analytical approaches. Approaches comparing a cell's genome to a control bulk sample miss common mutations, while approaches to find such mutations from bulk suffer from low sensitivity. We developed a tool, All2, which enables accurate filtering of mutations in a cell without the need for data from bulk(s). It is based on pair-wise comparisons of all cells to each other where every call for base pair substitution and indel is classified as either a germline variant, mosaic mutation, or false positive. As All2 allows for considering dropped-out regions, it is applicable to whole genome and exome analysis of cloned and amplified cells. By applying the approach to a variety of available data, we showed that its application reduces false positives, enables sensitive discovery of high frequency mutations, and is indispensable for conducting high resolution cell lineage tracing.

Indexed as

ExomeSoftwareExome SequencingHigh-Throughput Nucleotide SequencingINDEL MutationMutation

Identifiers

PMID35442945
PMCPMC9060341
OpenAlexW4225294388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.